TherOx was founded upon a simple, compelling notion-that large quantities of oxygen can be saturated into fluids to form aqueous oxygen. But while the benefits of salvaging ischemic tissue by providing oxygen are well known, solving the delivery problem took longer than even TherOx expected, as did subsequent engineering and regulatory approval issues. In the meantime, the company's initial target market became less attractive because of subsequent device developments, notably coronary stents. TherOx is now focused on a new, huge clinical opportunity-acute myocardial infarctions. What has sustained the company through eight years of progress and disappointment is the promise of a true platform technology with applications in a variety of large, diverse markets. The company therefore provides an answer to the question: How does a device start-up take eight years just to get to Phase II clinical trials and still survive?
by Stephen Levin
What's the dream of every medical device start-up? How about being the only company on the market with a new technology that's likely to be easily understood and embraced by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
